

09/673798

CJC
PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to:
Attention: Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

August 11, 2005
Date

Jeanne Lupton
Jeanne Lupton

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors : Xavier Paliard
Patent No. : 6,919,318 B1
Issue Date : July 19, 2005
Title : ENHANCING IMMUNE RESPONSES TO GENETIC
IMMUNIZATION BY USING A CHEMOKINE

Certificate
AUG 18 2005
of Correction

Docket No.: PP-1521.101

Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION

Sir:

A certificate of correction is respectfully requested in the above-identified patent.

The following corrections are requested:

On the cover page, Item (60), delete "PCT/US99/08802, filed on April 22, 1999", and insert in lieu thereof --60/082,600 filed on April 22, 1998--. The attached Corrected Filing Receipt, mailed April 30, 2001, and Declaration, executed October 18, 2000, indicate the correct provisional and PCT application information.

Col. 8, line 64, delete "a lymphocyte" and insert in lieu thereof --a B lymphocyte--. The attached Examiner's Amendment of Claim 31 found on Pages 2-3 of the Notice of Allowability mailed December 3, 2004, indicates that this change was made by the Examiner but not incorporated into the patent by the Patent Office.

AUG 19 2005

Attached is form PTO/SB/44, which indicates the corrections to be made, by reference to the column and line numbers in the printed patent. Because the errors were made by the Patent Office, no fee is necessary.

Respectfully submitted,

Dated: August 11, 2005

By



Helen Lee

Registration No. 39,270

Chiron Corporation
Intellectual Property – R440
P.O. Box 8097
Emeryville, California 94662-8097
Telephone 510-923-2192
Facsimile 510-655-3542

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,919,381 B1
DATED : July 19, 2005
INVENTOR(S) : Xavier Paliard

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Cover page, (60), delete "PCT/US99/08802, filed on April 22, 1999" and insert in lieu thereof --60/082,600 filed on April 22, 1998--.

Col. 9, line 64, delete "a lymphocyte" and insert in lieu thereof --a B lymphocyte--.

MAILING ADDRESS OF SENDER:

Chiron Corporation
Intellectual Property - R440 -P.O. Box 8097
Emeryville, CA 94662-8097

PATENT NO.

6,919,381 B1

No. of additional copies

1



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

AUG 19 2005

DETAILED ACTION

The amendment and response filed on 11/12/04 has been entered. Claims 21, 22 have been canceled. Claims 11, 16, 32 have been amended. Claims 1-7, 10, 11, 16-20, 23-32 are pending and under current examination.

All of the amendments have been thoroughly reviewed and entered. The previous rejections in the Office action mailed 9/9/04 are withdrawn in view of the amendments.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Michael Moran on November 23, 2004.

The claims have been amended as follows:

Claim 30 has been canceled.

Claim 31. (currently amended) A method of enhancing an immune response to a viral immunogen in a mammal comprising the step of:

Art Unit: 1632

intramuscularly or intradermally administering to the mammal (i) a B lymphocyte chemoattractant (BLC) or a polynucleotide encoding a B lymphocyte chemoattractant (BLC) ~~a first polynucleotide encoding a chemokine~~ and (ii) a plasmid comprising a sequence encoding a viral immunogen, wherein (i) and (ii) are administered successively in any order, and whereby an immune response to the viral immunogen is enhanced.

Conclusion

Claims 1-7, 10, 11, 16-20, 23-29, 31, 32 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Q. Janice Li** whose telephone number is 571-272-0730. The examiner can normally be reached on 9:30 am - 7 p.m., Monday through Friday, except every other Wednesday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Amy Nelson** can be reached on 571-272-0804. The fax numbers for the organization where this application or proceeding is assigned are **703-872-9306**.

Any inquiry of formal matters can be directed to the patent analyst, **Dianlece Jacobs**, whose telephone number is (571) 272-0532.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now

COPY



UNITED STATES PATENT AND TRADEMARK OFFICE


COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/673,798	10/18/2000	1642	986	PP01521.101	5	29	2

CONFIRMATION NO. 3092

CORRECTED FILING RECEIPT

Anne S Dollard
Chiron Corporation
P O Box 8097
Intellectual Property R338
Emeryville, CA 94662-8097



C000000006019974*

Date Mailed: 04/30/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Xavier Paliard, San Francisco, CA;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US99/08802 04/22/1999
WHICH CLAIMS BENEFIT OF 60/082,600 04/22/1998

Foreign Applications

If Required, Foreign Filing License Granted 01/11/2001

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

PP01521.101
ASD
5/18/01 PID
4/18/02
DATE 5/4/01

Title

Enhancing immune responses to genetic immunization by using a chemokine


Preliminary Class

424

Data entry by : SMALLWOOD, EAON

Team : 1600

Date: 04/30/2001



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231



COPY

Docket No.
PP01521.101

Declaration For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

ENHANCING IMMUNE RESPONSES TO GENETIC IMMUNIZATION BY USING A CHEMOKINE

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 22 April 1999 as United States Application No. or PCT International

Application Number PCT/US99/08802

and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

N/A

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

22 April 1998

(Filing Date)

(Filing Date)

~~(Filing Date)~~

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, CFR Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)


(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Paliard, XAVIER	
Sole or first inventor's signature 	Date 18 October 2000
Residence 148 SATURN ST, #1 SAN FRANCISCO, CA 94114	
Citizenship USA	
Post Office Address same as above	

Full name of second inventor, if any	
Second inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of third inventor, if any	
Third inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of fourth inventor, if any	
Fourth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	